Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years

Inclusion Criteria: * Children age 1-5 years inclusive at the time of screening; * Residing in Lambaréné for the duration of the study; * Written informed consent obtained before screening and study start, respectively; * Available to participate in follow-up for the duration of study (13 months); * General good health based on history and clinical examination. Exclusion Criteria: * Previous vaccination with any other malaria candidate vaccine. * Concomitant vaccination with a investigational vaccine or a rabies vaccine; * Use of a investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first study vaccination, or planned use up to 30 days after the third vaccination; * Chronic administration (defined as more than 14 days) of immuno-suppressants or other immune-modifying drugs within six months prior to the first vaccination. This includes any dose level of oral steroids or inhaled steroids, but not topical steroids; * Confirmed or suspected immunosuppressive or immuno-deficient condition, including human immunodeficiency virus (HIV) infection; * Confirmed or suspected autoimmune disease; * History of allergic reactions or anaphylaxis to immunizations or to any of the vaccine components, or of serious allergic reactions to any substance, requiring hospitalization or emergent medical care; * History of splenectomy; * Laboratory evidence of liver disease (Alanine aminotransferase \[ALT\] greater than 1.25 times the upper limit of normal (\<45 U/L) of the testing laboratory); * Laboratory evidence of renal disease (serum creatinine greater than the upper limit of normal of the testing laboratory, or more than trace protein or blood on urine dipstick testing); * Laboratory evidence of haematological disease (absolute leukocyte count 3.5-11/µL, absolute lymphocyte count 560-5280/µL, platelet count 120,000-400,000/µL, or haemoglobin 10.0-16.5g/dL); * Administration of immunoglobulins and/or any blood products within the three months preceding the first study vaccination or planned administration during the study period; * Simultaneous participation in any other interventional clinical trial; * Acute or chronic pulmonary, cardiovascular, hepatic, renal or neurological condition, malnutrition, or any other clinical findings that in the opinion of the clinical investigator, may increase the risk of participating in the study; * Other condition that in the opinion of the clinical investigator would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol.